MedTrace Logo

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

NCT07228221 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-11-14

No results posted yet for this study

Summary

The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.

Conditions

Interventions

DEVICE

iStent infinite trabecular micro-bypass system model iS3

surgery perfomed using the iStent infinite trabecular micro-bypass system model iS3

DRUG

iDose TR (Travoprost intracameral Implant) 75mcg

surgery performed using the iDose TR (Travoprost intracameral Implant) 75mcg

Sponsors & Collaborators

  • Glaukos Corporation

    collaborator INDUSTRY

  • Jonathon Myers

    lead OTHER

Principal Investigators

  • Dilru Amarasekera, MD · Wills Eye Hospital Glaucoma Research

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-05
Primary Completion
2031-08-30
Completion
2031-12-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07228221 on ClinicalTrials.gov